Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
September 22, 2021 10:07 pm ET
Delayed at least 20 minutes

Latest news, events & financials

September 19, 2021

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)

September 18, 2021

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

September 18, 2021

Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting

View all

October 28, 2021

Earnings

Merck & Co., Inc. Q3 2021 Earnings Call

Add to Calendar

February 03, 2022

Earnings

Merck & Co., Inc. Q4 2021 Earnings Call

Add to Calendar

April 28, 2022

Earnings

Merck & Co., Inc. Q1 2022 Earnings Call

Add to Calendar

July 28, 2022

Earnings

Merck & Co., Inc. Q2 2022 Earnings Call

Add to Calendar

View all

2Q21 Merck Earnings Announcement
PDF

2Q21 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Oncology Event at ESMO 2021

Dial: (833) 353-0277 or (469) 886-1947

Access Code: 4574124

Webcast

Presentation

Transcript

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2020/2021 ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our second-quarter 2021 financial results

Merck announced second-quarter 2021 sales from continuing operations (excluding Organon) of $11.4 billion, 22% above second-quarter 2020. Excluding the impact from foreign exchange, sales grew 19%. The company anticipates full-year 2021 revenue range to be between $46.4 billion and $47.4 billion, including a positive impact from foreign exchange of less than 2%. Take a look […]

Next: Our second-quarter 2021 financial results